Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial

BACKGROUND: Recent trials have revealed that sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are effective against hyperglycemia and also reduce micro- and macro-vascular complications in patients with type 2 diabetes mellitus (T2DM). Most of the beneficial cardiovascular effects have been inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Gohari, Sepehr, Reshadmanesh, Tara, Khodabandehloo, Hadi, Fathi, Mojtaba, Ahangar, Hassan, Arsang-Jang, Shahram, Ismail-Beigi, Faramarz, Ghanbari, Samin, Dadashi, Mohsen, Muhammadi, Muhammad Javad, Gohari, Sheida, Ghaffari, Saeid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242278/
https://www.ncbi.nlm.nih.gov/pubmed/34193056
http://dx.doi.org/10.1186/s12872-021-02131-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242278/
https://www.ncbi.nlm.nih.gov/pubmed/34193056
http://dx.doi.org/10.1186/s12872-021-02131-1

Ejemplares similares